BID | 248.42 | ASK | 248.60 | ||
Open | 249.38 | Previous Close | 248.38 | ||
Pre-Market | 246.97 | After-Market | - | ||
-1.41 -0.57% | - - |
Target Price | 310.50 | Analyst Rating | Strong Buy 1.44 | |
Potential % | 24.09 | Finscreener Ranking | ★★★ 48.73 | |
Insiders Trans % 3/6/12 mo. | -67/-75/-95 | Value Ranking | ★+ 44.98 | |
Insiders Value % 3/6/12 mo. | -99/-99/-100 | Growth Ranking | ★★★★+ 64.63 | |
Insiders Shares Cnt. % 3/6/12 mo. | -99/-99/-100 | Income Ranking | ★★ 39.69 | |
Price Range Ratio 52W % | 21.18 | Earnings Rating | Sell | |
Market Cap | 181.09B | Earnings Date | 20th Apr 2023 | |
Alpha | 0.01 | Standard Deviation | 0.06 | |
Beta | 0.83 |
Today's Price Range 248.28252.80 | 52W Range 233.71303.82 | 5 Year PE Ratio Range 21.3068.40 |
Summary:
Neutral
Technical Indicators: | Neutral |
Moving Averages: | Sell |
Performance | |||
---|---|---|---|
1 Week | 2.59% | ||
1 Month | -0.69% | ||
3 Months | -3.98% | ||
6 Months | -6.77% | ||
1 Year | -15.49% | ||
3 Years | 100.61% | ||
5 Years | 154.77% | ||
10 Years | 307.34% |
Mngmt Effectiveness | Value | Industry | S&P 500 | US Markets |
---|---|---|---|---|
ROE (5Y Avg) | 8.38 | |||
ROE last 12 Months | 16.73 | |||
ROA (5Y Avg) | 3.15 | |||
ROA last 12 Months | 8.80 | |||
ROC (5Y Avg) | 6.14 | |||
ROC last 12 Months | 10.59 | |||
Return on invested Capital Q | 2.44 | |||
Return on invested Capital Y | 2.78 | |||
Assets Turnover | 0.30 | |||
Receivables Turnover | 5.50 |
Valuation | Value | Industry | S&P 500 | US Markets |
---|---|---|---|---|
27.90 | ||||
4.06 | ||||
8.04 | ||||
22.40 | ||||
43.40 | ||||
11.27 | ||||
-14.25 | ||||
62.25 | ||||
199.57B | ||||
Forward PE | 23.58 | |||
PEG | 2.33 |
Financial Strength | Value | Industry | S&P 500 | US Markets |
---|---|---|---|---|
1.20 | ||||
1.80 | ||||
0.28 | ||||
0.42 | ||||
41.30 | ||||
Leverage Ratio | 1.80 |
Profitability | Value | Industry | S&P 500 | US Markets |
---|---|---|---|---|
60.70 | ||||
26.80 | ||||
34.00 | ||||
19.40 | ||||
21.54 |
Revenue | Value | Industry | S&P 500 | US Markets |
---|---|---|---|---|
23.10B | ||||
31.74 | ||||
15.37 | ||||
9.03 |
Dividends | Value | Industry | S&P 500 | US Markets |
---|---|---|---|---|
0.39 | ||||
1.00 | ||||
8.76 | ||||
8.85 | ||||
Payout ratio | 10.00 |
Earnings History | Estimate | Reported | Surprise % |
---|---|---|---|
Q04 2022 | 2.46 | 2.87 | 16.67 |
Q03 2022 | 2.24 | 2.56 | 14.29 |
Q02 2022 | 2.35 | 2.76 | 17.45 |
Q01 2022 | 2.65 | 2.76 | 4.15 |
Q04 2021 | 2.50 | 2.69 | 7.60 |
Q03 2021 | 2.14 | 2.39 | 11.68 |
Q02 2021 | 2.04 | 2.46 | 20.59 |
Q01 2021 | 1.67 | 2.52 | 50.90 |
Earnings Per End | Estimate | Revision % | Trend |
---|---|---|---|
12/2022 QR | 2.44 | -7.58 | Negative |
12/2022 FY | 10.53 | 1.25 | Positive |
3/2023 QR | 2.49 | -7.09 | Negative |
12/2023 FY | 10.38 | -2.54 | Negative |
Next Report Date | 20th Apr 2023 |
Estimated EPS Next Report | 2.26 |
Estimates Count | 9 |
EPS Growth Next 5 Years % | 12.00 |
Volume Overview | |
---|---|
Volume | 2.60M |
Shares Outstanding | 728.58K |
Shares Float | 648.34M |
Trades Count | 38.79K |
Dollar Volume | 649.24M |
Avg. Volume | 2.46M |
Avg. Weekly Volume | 2.52M |
Avg. Monthly Volume | 2.42M |
Avg. Quarterly Volume | 2.44M |
Danaher Corporation (NYSE: DHR) stock closed at 248.38 per share at the end of the most recent trading day (a 1.46% change compared to the prior day closing price) with a volume of 1.74M shares and market capitalization of 181.09B. Is a component of S&P 500, Russell 1000 indices and it is traded on NYSE exchange. The company belongs in the Medical Diagnostics & Research industry, Healthcare sector and employs 69000 people. Danaher Corporation CEO is Rainer M. Blair.
The one-year performance of Danaher Corporation stock is -15.49%, while year-to-date (YTD) performance is -6.42%. DHR stock has a five-year performance of 154.77%. Its 52-week range is between 233.708 and 303.82, which gives DHR stock a 52-week price range ratio of 21.18%
Danaher Corporation currently has a PE ratio of 27.90, a price-to-book (PB) ratio of 4.06, a price-to-sale (PS) ratio of 8.04, a price to cashflow ratio of 22.40, a PEG ratio of 2.32, a ROA of 8.80%, a ROC of 10.59% and a ROE of 16.73%. The company’s profit margin is 21.54%, its EBITDA margin is 34.00%, and its revenue ttm is $23.10 Billion , which makes it $31.74 revenue per share.
Of the last four earnings reports from Danaher Corporation, there were 4 positive earnings surprise and 0 negative earnings surprise. The company has EPS estimate of $2.26 for the next earnings report. Danaher Corporation’s next earnings report date is 20th Apr 2023.
The consensus rating of Wall Street analysts for Danaher Corporation is Strong Buy (1.44), with a target price of $310.5, which is +24.09% compared to the current price. The earnings rating for Danaher Corporation stock is Sell (calculated from actual period earnings estimates revision (80% weight) and previous period earnings surprise (20% weight)).
Danaher Corporation has a dividend yield of 0.39% with a dividend per share of $1.00 and a payout ratio of 10.00%.
Danaher Corporation has a Neutral technical analysis rating based on Technical Indicators (ADX : 11.03, ATR14 : 5.82, CCI20 : 26.98, Chaikin Money Flow : 0.05, MACD : -3.34, Money Flow Index : 46.95, ROC : -1.88, RSI : 48.63, STOCH (14,3) : 65.27, STOCH RSI : 1.00, UO : 57.82, Williams %R : -34.73), Simple Moving Averages and Exponential Moving Averages.
Aggregated Insider Trades of Danaher Corporation in the last 12-months were: Alan G. Spoon (Option Excercise at a value of $177 292), Alan G. Spoon (Sold 500 shares of value $126 465 ), Georgeann F. Couchara (Sold 1 884 shares of value $511 719 ), Jennifer Honeycutt (Option Excercise at a value of $540 530), Jennifer Honeycutt (Sold 8 211 shares of value $2 175 915 ), Joakim Weidemanis (Option Excercise at a value of $382 603), Joakim Weidemanis (Sold 28 008 shares of value $7 450 727 ), John T. Schwieters (Option Excercise at a value of $175 735), Matthew R. McGrew (Option Excercise at a value of $1 082 881), Matthew R. McGrew (Sold 18 935 shares of value $5 201 845 ), Mitchell P. Rales (Buy at a value of $24 789), Rainer M. Blair (Option Excercise at a value of $1 673 572), Rainer M. Blair (Sold 25 000 shares of value $7 500 000 ), Raymond C. Stevens (Option Excercise at a value of $851 686), Raymond C. Stevens (Sold 8 410 shares of value $2 222 514 ), Walter G. Lohr (Option Excercise at a value of $175 735), Walter G. Lohr (Sold 3 906 shares of value $1 069 619 )
Analyst Ratings | Current | 1 M ago | 3 M ago |
---|---|---|---|
Strong Buy | |||
Moderate Buy | |||
Hold | |||
Moderate Sell | |||
Strong Sell | |||
Summary Rating | Strong Buy | Strong Buy | Strong Buy |
In 1984, Danaher's founders transformed a real estate organization into an industrial-focused manufacturing company. Through a series of mergers, acquisitions, and divestitures, including the Fortive separation in 2016, Danaher now focuses primarily on manufacturing scientific instruments and consumables in three segments: life sciences, diagnostics, and environmental and applied solutions. In late 2019, Danaher separated from its dental business through an initial public offering process, and in early 2020, it acquired GE's Biopharma business, now called Cytiva, which added to its life sciences segment.
CEO: Rainer M. Blair
Telephone: +1 202 828-0850
Address: 2200 Pennsylvania Avenue, North West, Washington 20037-1701, DC, US
Number of employees: 69 000
Tue, 21 Mar 2023 12:50 GMT Analysts Offer Insights on Healthcare Companies: Biogen (BIIB), Danaher (DHR) and Blueprint Medicines (BPMC)
- TipRanks. All rights reserved.Mon, 06 Feb 2023 11:30 GMT Analysts Are Bullish on These Healthcare Stocks: Danaher (DHR), Sanofi-Aventis Sa (SNY)
- TipRanks. All rights reserved.Sat, 04 Feb 2023 22:09 GMT Danaher has expressed takeover interest in Catalent, Bloomberg says
- TipRanks. All rights reserved.Copyright © 2016-2023 Finscreener.org. All Rights Reserved.
Disclaimer: Before deciding to trade you should carefully consider your investment objectives, level of experience and your risk appetite. Forex and Tradegate data is a real-time with a 30 second refresh. Prices may not be accurate and may differ from the actual market price. Prices on the website are indicative and solely for informational purposes, not for trading purposes or advice. Please be aware of the risks associated with trading the on financial markets, it is one of the riskiest investment forms. Past performance does not guarantee future profits. We take no responsibility for any losses that may arise as a result of the data contained on this website. The content and the website are provided "as is", without any warranties. In no event will Finscreener.org, its employees, owners, directors, affiliates, partners, data provider, third party or anyone else liable to anyone else for any decision made regarding information on this website.
All rights reserved. Financial Market Data powered by Quotemedia.com. All rights reserved. View the Terms of Use. NYSE/NYSE MKT (AMEX) data delayed 20 minutes. NASDAQ and other data delayed 15 minutes unless otherwise indicated. Copyright © 2023. All market data is provided by Quotemedia.com. Futures: at least a 10 minute delay. Information is provided 'as is' and solely for informational purposes, not for trading purposes or advice. To see all exchange delays and terms of use, please see disclaimer. The Cryptocurrency Market real-time data provided by Cryptocompare.com
General partner of Finscreener is SLOVAKODATA, a.s.
Don´t have an account? Register
Looks like you are using AdBlock.
The revenue earned from advertising enables us to provide the quality content you are trying to reach on this website. In order to view this page, please disable AdBlock or purchase Premium.
Sign in if you already have Premium account.
This could take some time, please wait.